Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K W Zamkoff

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Cellular Immunology|January 1, 1988
Differential effect on fresh and cultured T cells of PHA-induced changes in free cytoplasmic calcium: relation to IL-2 receptor expression, IL-2 production, and proliferationN P Watman, L Crespo, B Davis, et al.
Journal of Biological Response Modifiers|October 1, 1989
A phase I trial of subcutaneously administered recombination tumor necrosis factor to patients with advanced malignancyK W Zamkoff, N B Newman, A R Rudolph, et al.
American Journal of Hematology|April 1, 1983
The in vitro effects of vincristine on peripheral blood leukocyte progenitor cells (CFU-C) in patients in blast crisis of chronic granulocytic leukemia: correlation with clinical responseJ Goldberg, K W Zamkoff, D A Nelson, et al.
Annals of Clinical and Laboratory Science|May 1, 1983
T-cell prolymphocytic leukemia with a suppressor phenotypeA T Planas, K W Zamkoff, B J Poiesz, et al.
Archives of Internal Medicine|September 1, 1985
Thyrotoxic thyroiditis after radiotherapy for Hodgkin's diseaseJ B Blitzer, F P Paolozzi, A J Gottlieb, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|February 1, 1992
A phase I trial of recombinant human macrophage colony-stimulating factor by rapid intravenous infusion in patients with refractory malignancyK W Zamkoff, J Hudson, E S Groves, et al.
Hematological Oncology|March 1, 1990
Inducible lymphokine-activated killer (LAK) cell activity in the peripheral blood of patients with relapsed/refractory non-Hodgkin's lymphoma (NHL)K W Zamkoff, N P Watman, D B Duggan, et al.
Bone Marrow Transplantation|March 7, 2003
Fatal EBV-related post-transplant lymphoproliferative disorder (LPD) after matched related donor nonmyeloablative peripheral blood progenitor cell transplantK W Zamkoff, S Bergman, M W Beaty, et al.
Medical and Pediatric Oncology|January 1, 1983
Acute nonlymphocytic leukemia complicated by severe cytophagocytosis of formed blood elements by nonmalignant histiocytes: cause of significant clinical morbidityM E Theodorakis, K W Zamkoff, F R Davey, et al.
Bone Marrow Transplantation|March 9, 2004
High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphomaK W Zamkoff, M D Matulis, A C Mehta, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Cellular Immunology|January 1, 1988
Differential effect on fresh and cultured T cells of PHA-induced changes in free cytoplasmic calcium: relation to IL-2 receptor expression, IL-2 production, and proliferationN P Watman, L Crespo, B Davis, et al.
Journal of Biological Response Modifiers|October 1, 1989
A phase I trial of subcutaneously administered recombination tumor necrosis factor to patients with advanced malignancyK W Zamkoff, N B Newman, A R Rudolph, et al.
American Journal of Hematology|April 1, 1983
The in vitro effects of vincristine on peripheral blood leukocyte progenitor cells (CFU-C) in patients in blast crisis of chronic granulocytic leukemia: correlation with clinical responseJ Goldberg, K W Zamkoff, D A Nelson, et al.
Annals of Clinical and Laboratory Science|May 1, 1983
T-cell prolymphocytic leukemia with a suppressor phenotypeA T Planas, K W Zamkoff, B J Poiesz, et al.
Archives of Internal Medicine|September 1, 1985
Thyrotoxic thyroiditis after radiotherapy for Hodgkin's diseaseJ B Blitzer, F P Paolozzi, A J Gottlieb, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|February 1, 1992
A phase I trial of recombinant human macrophage colony-stimulating factor by rapid intravenous infusion in patients with refractory malignancyK W Zamkoff, J Hudson, E S Groves, et al.
Hematological Oncology|March 1, 1990
Inducible lymphokine-activated killer (LAK) cell activity in the peripheral blood of patients with relapsed/refractory non-Hodgkin's lymphoma (NHL)K W Zamkoff, N P Watman, D B Duggan, et al.
Bone Marrow Transplantation|March 7, 2003
Fatal EBV-related post-transplant lymphoproliferative disorder (LPD) after matched related donor nonmyeloablative peripheral blood progenitor cell transplantK W Zamkoff, S Bergman, M W Beaty, et al.
Medical and Pediatric Oncology|January 1, 1983
Acute nonlymphocytic leukemia complicated by severe cytophagocytosis of formed blood elements by nonmalignant histiocytes: cause of significant clinical morbidityM E Theodorakis, K W Zamkoff, F R Davey, et al.
Bone Marrow Transplantation|March 9, 2004
High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphomaK W Zamkoff, M D Matulis, A C Mehta, et al.
Pageof 3